Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Halo Completes Mirabel Acquisition | Contract Pharma

What are you searching for?

Sign in
Breaking News

Halo Completes Mirabel Acquisition

Montreal facility to add dosage forms, EU reach

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

On July 31, Halo Pharmaceutical completed its acquisition of Teva‘s Mirabel site in Montreal, Quebec. The transaction had been expected to close by June, but labor negotiations extended the time frame.

The site, which Teva gained in its acquisition of Ratiopharm, adds non-sterile creams and ointments and high volume liquids capabilities to Halo’s dosage form portfolio. The facility also provides immediate access to supply clients’ products into the European market. Halo will manufacture several products for Teva as part of a trailing supply agreement.

Said Clive V. Bennett, Halo’s president and chief executive officer, “In addition to introducing new clients to the Montreal site for commercial manufacturing, we plan to re-start pharmaceutical product development activities in Montreal in the very near future. This is an important and high-tech area of growth for Halo, and is already a significant facet of our activities in the existing Halo facility in Whippany, NJ. Importantly for both Halo and for our clients, the Montreal site offers substantial R&D tax credit opportunities for pharmaceutical development work conducted there.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics